Amgevita (adalimumab) for Rheumatoid Arthritis | Amgen
BioSpace Feature: A Look at Miracle Drug Humira's Journey to Proven Efficacy | BioSpace
First clinical trial with D2E7 (Humira) - YouTube
Abbvie initiates new clinical trial to evaluate humira® (adalimumab) for the treatment of fingernail psoriasis - Drug Target Review
HUMIRA (adalimumab) Dermatology Healthcare Professional Site
Adalimumab - Wikipedia
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial - Journal of the American Academy of Dermatology
Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology
Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty‐six‐week phase 3 open‐label study - Yamasaki - 2020 - The Journal of Dermatology - Wiley Online Library
AbbVie's Humira sales continue to climb beyond its patent expiration - Clinical Trials Arena
Humira, INN - adalimumab
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis | Arthritis Research & Therapy | Full Text
HUMIRA (adalimumab) Dermatology Healthcare Professional Site
Phase III clinical trials conducted for adalimumab biosimilars; data... | Download Scientific Diagram
VARSITY Ulcerative Colitis Clinical Trial | Entyvio® (vedolizumab)
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis | NEJM
HUMIRA® (adalimumab) for Rheumatoid Arthritis (RA)
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator- controlled phase 3 trial - The Lancet
HUMIRA (adalimumab) Dermatology Healthcare Professional Site
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed | Annals of the Rheumatic Diseases
Ulcerative Colitis Remission & HUMIRA® Results (adalimumab)
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial - Gastroenterology
Adalimumab: a review of the reference product and biosimilars | BS
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial - The Lancet
VARSITY Ulcerative Colitis Clinical Trial | Entyvio® (vedolizumab)
Humira Biosimilars Clinical Trial Insight - Research and Markets
